Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor.
Kjaergaard J, Peng L, Cohen PA, Drazba JA, Weinberg AD, Shu S. Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor. J Immunol. 2001 Dec 01; 167(11):6669-77.
-
Adjuvants, Immunologic
-
Animals
-
Antibodies, Monoclonal
-
Antineoplastic Combined Chemotherapy Protocols
-
Brain Neoplasms
-
CD4-Positive T-Lymphocytes
-
CD8-Positive T-Lymphocytes
-
Cell Movement
-
Female
-
Fibrosarcoma
-
Immunotherapy, Adoptive
-
Injections, Intravenous
-
Injections, Subcutaneous
-
Interleukin-2
-
L-Selectin
-
Lung Neoplasms
-
Lymph Nodes
-
Lymphocyte Activation
-
Lymphocytes, Tumor-Infiltrating
-
Melanoma, Experimental
-
Membrane Glycoproteins
-
Mice
-
Mice, Inbred C57BL
-
OX40 Ligand
-
Receptors, OX40
-
Receptors, Tumor Necrosis Factor
-
T-Lymphocytes
-
Tumor Necrosis Factor Receptor Superfamily, Member 7
-
Tumor Necrosis Factors
-
Up-Regulation